CT Antigen TCR-Engineered T Cells for Myeloma
Phase 1
Terminated
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Treatment with NY-ESO-1c259-modified T cells
- First Posted Date
- 2013-07-04
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Adaptimmune
- Target Recruit Count
- 6
- Registration Number
- NCT01892293
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
Phase 1
Completed
- Conditions
- Ovarian Cancer
- Interventions
- Biological: NYESO-1c259 T cells
- First Posted Date
- 2012-03-30
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- Adaptimmune
- Target Recruit Count
- 9
- Registration Number
- NCT01567891
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma
Phase 1
Terminated
- Conditions
- Melanoma
- Interventions
- Genetic: Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T
- First Posted Date
- 2011-05-09
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Adaptimmune
- Target Recruit Count
- 4
- Registration Number
- NCT01350401
- Locations
- 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
© Copyright 2025. All Rights Reserved by MedPath